https://tg003inhibitor.com/wis....e-properties-which-d
TECHNIQUES We methodically searched PubMed and Embase on Cochrane Central enroll of Controlled tests (CENTRAL) from the very first day to August 1, 2019. General threat (RR) and weighted mean difference (WMD) were used to evaluate medical outcomes. RESULTS Seven studies were pooled with 3889 patients. Subcutaneous shot of Galcanezumab at 120 mg, 240 mg leads to a statistically significant response rate to treat migraine compared with placebo (120 mg RR = 1.51; 95% CI, 1.33 to 1.70; P less then 0.001; 240 mg RR = 1
Like
Comment
Share
